By Counterforce Health Team in Orladeyo (berotralstat) —

Myths vs. Facts: Getting Orladeyo (berotralstat) Covered by Aetna (CVS Health) in North Carolina

Answer Box: Get Orladeyo (berotralstat) Covered by Aetna (CVS Health) in North Carolina

Eligibility: Adults and pediatric patients ≥12 years with confirmed hereditary angioedema (HAE) requiring prophylaxis. Fastest path: Have your HAE specialist submit prior authorization with C1-INH testing, attack documentation, and failed alternatives. First step today: Call Aetna at 1-866-752-7021 to verify Orladeyo's formulary status and PA requirements. If denied, you have 180 days for internal appeals and 120 days for North Carolina's Smart NC external review program.

Table of Contents

  1. Why Myths About Specialty Drug Coverage Persist
  2. Common Myths vs. Facts About Orladeyo Coverage
  3. What Actually Influences Aetna Approval
  4. Top 5 Mistakes to Avoid
  5. Quick Action Plan: Three Steps to Take Today
  6. North Carolina Appeals Process
  7. FAQ
  8. Resources

Why Myths About Specialty Drug Coverage Persist

Orladeyo (berotralstat) costs approximately $44,484 per 28-day pack, making it one of the most expensive oral medications for hereditary angioedema prevention. When patients face this sticker shock—or receive their first denial letter—myths and misconceptions quickly spread through online forums and support groups.

The complexity doesn't help. Aetna (CVS Health) manages specialty medications through multiple channels: CVS Caremark for pharmacy benefits, CVS Specialty for home delivery, and various prior authorization pathways depending on your specific plan type. Add North Carolina's unique external review system through Smart NC, and it's no wonder patients feel overwhelmed.

But here's the reality: most Orladeyo denials are overturnable when you understand the actual approval criteria and avoid common documentation mistakes. Let's separate fact from fiction.

Common Myths vs. Facts About Orladeyo Coverage

Myth 1: "If my doctor prescribes Orladeyo, Aetna has to cover it"

Fact: Prescription alone doesn't guarantee coverage. Aetna requires prior authorization for Orladeyo, including documented HAE diagnosis via C1-INH testing, attack frequency documentation, and evidence of medical necessity for prophylaxis rather than on-demand treatment.

Myth 2: "Orladeyo is automatically covered because it's FDA-approved for HAE"

Fact: FDA approval doesn't equal insurance coverage. Orladeyo typically appears on Tier 5 (specialty) formularies with the highest cost-sharing and strictest utilization management requirements.

Myth 3: "I can skip step therapy because HAE is a rare disease"

Fact: Even rare disease treatments often require step therapy. Aetna may require trials of other HAE prophylaxis options (like Takhzyro or C1-INH products) before approving Orladeyo, unless you document medical contraindications or prior failures.

Myth 4: "Emergency room visits prove I need Orladeyo"

Fact: ER visits for acute HAE attacks don't automatically justify prophylaxis. Aetna looks for specific attack frequency patterns (typically ≥2 severe attacks per month) and failed response to on-demand treatments before approving preventive therapy.

Myth 5: "Age restrictions don't apply to life-threatening conditions"

Fact: Aetna follows FDA labeling strictly. Orladeyo is only approved for patients ≥12 years old. Younger patients need alternative HAE treatments regardless of attack severity.

Myth 6: "I can use any pharmacy for specialty medications"

Fact: Specialty drugs like Orladeyo must go through CVS Specialty pharmacy for Aetna members. Using retail pharmacies will result in coverage denial.

Myth 7: "If Aetna denies my appeal, that's final"

Fact: North Carolina offers robust external review rights through Smart NC. You have 120 days after final internal denial to request independent review, with expedited options for urgent cases.

Myth 8: "Generic alternatives work just as well as Orladeyo"

Fact: There are no generic versions of berotralstat. However, Aetna may prefer other HAE prophylaxis options with better cost-effectiveness profiles, requiring you to document why Orladeyo specifically is medically necessary.

What Actually Influences Aetna Approval

Clinical Documentation Requirements

  • Confirmed HAE diagnosis: C1-INH antigen and functional levels, C4 levels, genetic testing for HAE-nC1-INH subtypes
  • Attack documentation: Detailed logs showing frequency, severity, anatomical locations, and impact on daily functioning
  • Prior treatment history: Documentation of failed or contraindicated alternatives (antihistamines, corticosteroids, other prophylaxis)
  • Specialist involvement: Referral to or consultation with HAE specialist or immunologist

Administrative Factors

  • Formulary status: Check current tier placement and any quantity limits
  • Site of care: Oral medications like Orladeyo have fewer site restrictions than infusions
  • Age verification: Must be ≥12 years with documented birthdate
  • Plan type: Commercial, Medicare, or Medicaid plans have different approval pathways
From our advocates: We've seen Orladeyo approvals succeed when families maintain detailed attack diaries for 3-6 months before requesting prophylaxis. Include missed work/school days, ER visits, and functional limitations—not just clinical symptoms. This real-world evidence often tips the balance in your favor during peer-to-peer reviews.

Top 5 Mistakes to Avoid

1. Submitting Incomplete HAE Diagnosis Documentation

The mistake: Sending only recent C1-INH levels without confirming HAE subtype or ruling out acquired angioedema. The fix: Ensure repeat testing (≥1 month apart), family history documentation, and C1q levels to exclude acquired causes. Reference BCBSMS HAE policy for complete testing requirements.

2. Requesting Orladeyo for Acute Treatment

The mistake: Positioning Orladeyo as rescue therapy for active attacks. The fix: Emphasize prophylactic indication. Document that you understand Orladeyo is for prevention, not acute treatment, and that you have appropriate rescue medications available.

3. Bypassing CVS Specialty Pharmacy

The mistake: Trying to fill Orladeyo at local retail pharmacies. The fix: Work with your prescriber to send prescriptions directly to CVS Specialty. Call 1-800-237-2767 to set up specialty pharmacy services.

4. Missing Appeal Deadlines

The mistake: Waiting too long to file internal appeals or external review requests. The fix: Mark your calendar: 180 days for Aetna internal appeals, 120 days for North Carolina Smart NC external review after final internal denial.

5. Inadequate Step Therapy Documentation

The mistake: Not proving why other HAE prophylaxis options won't work. The fix: Document specific contraindications, prior failures, or intolerance to alternatives like Takhzyro, Haegarda, or Cinryze with dates and clinical details.

Quick Action Plan: Three Steps to Take Today

Step 1: Verify Current Coverage Status

Call Aetna member services at 1-866-752-7021. Ask specifically:

  • Is Orladeyo on my plan's formulary?
  • What tier is it on and what's my copay?
  • Does it require prior authorization?
  • Are there quantity limits?

Step 2: Gather Required Documentation

Contact your HAE specialist or prescriber to compile:

  • Complete C1-INH testing results with dates
  • Attack diary for the past 3-6 months
  • Documentation of failed alternative treatments
  • Current medication list and dosages

Step 3: Submit Prior Authorization

Have your prescriber submit PA through:

  • Aetna provider portal (preferred)
  • Fax: (verify current number with Aetna)
  • Phone: 1-866-752-7021 for medical benefit drugs

Include all clinical documentation and emphasize prophylactic indication for confirmed HAE.

North Carolina Appeals Process

If Aetna denies your Orladeyo request, North Carolina offers excellent consumer protections through the Smart NC program.

Internal Appeals with Aetna

  • Timeline: 180 days from denial date
  • Process: Two levels of internal review
  • Expedited option: Available for urgent medical situations
  • How to file: Call 1-866-752-7021 or submit through member portal

External Review through Smart NC

  • Eligibility: Must exhaust internal appeals first (except for expedited cases)
  • Timeline: 120 days after final internal denial to request
  • Decision timeframe: 45 days for standard review, 72 hours for expedited
  • Success rate: North Carolina's external review program has historically favored consumers in medical necessity disputes
  • How to file: Contact Smart NC at 1-855-408-1212 or visit the NC Department of Insurance website

Required Documents for Appeals

  • Original denial letter
  • Complete medical records supporting HAE diagnosis
  • Attack documentation and impact on quality of life
  • Evidence of failed alternative treatments
  • Prescriber letter of medical necessity

Counterforce Health specializes in turning insurance denials into targeted, evidence-backed appeals. Their platform helps identify the specific denial basis and drafts point-by-point rebuttals aligned with Aetna's own coverage policies, incorporating the right clinical evidence and procedural requirements for North Carolina appeals.

FAQ

Q: How long does Aetna prior authorization take for Orladeyo in North Carolina? A: Standard PA decisions typically take 15-30 days. Expedited reviews (for urgent medical situations) must be completed within 72 hours per North Carolina regulations.

Q: What if Orladeyo isn't on Aetna's formulary? A: Request a formulary exception through your prescriber. Provide clinical documentation showing medical necessity and why formulary alternatives aren't appropriate for your specific case.

Q: Can I get temporary supplies while waiting for approval? A: Aetna may provide a 30-day emergency supply for continuing therapy. For new prescriptions, ask your prescriber about manufacturer patient assistance programs during the approval process.

Q: Does step therapy apply if I failed other HAE treatments outside North Carolina? A: Yes, properly documented treatment failures from any location count toward step therapy requirements. Ensure your new North Carolina provider has complete records from previous treatments.

Q: What's the difference between medical benefit and pharmacy benefit coverage? A: Orladeyo typically falls under pharmacy benefit (CVS Caremark). However, if administered in a clinical setting, it might be covered under medical benefit with different PA requirements.

Q: How do I find an HAE specialist in North Carolina? A: Contact the Hereditary Angioedema Association for specialist referrals, or ask your current physician for immunology/allergy referrals with HAE experience.

Resources

Official Aetna Resources

North Carolina Consumer Protection

Clinical Resources

Patient Assistance

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions depend on your specific plan terms and clinical circumstances. Always consult with your healthcare provider and insurance plan directly for personalized guidance. For professional appeals assistance, Counterforce Health helps patients and clinicians navigate complex prior authorization and appeals processes with evidence-based strategies tailored to specific payer requirements.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.